There are remarkable disparities among patients of different races with prostate cancer;
however, the mechanism underlying this difference remains unclear. Here, we present a …

Treatments that target immune checkpoints, such as the one mediated by programmed cell
death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers …

Prostate cancer shows remarkable clinical heterogeneity, which manifests in spatial and
clonal genomic diversity. By contrast, the transcriptomic heterogeneity of prostate tumours is …

Prostate cancer is the second most common cancer in men worldwide 1 . Over the past
decade, large-scale integrative genomics efforts have enhanced our understanding of this …

Background Global disparities in prostate cancer (PCa) incidence highlight the urgent need
to identify genomic abnormalities in prostate tumors in different ethnic populations including …

Purpose : To understand the role of MALAT-1 in prostate cancer we evaluated its expression
in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve. …

Prostate cancer risk–associated variants have been reported in populations of European
descent, African-Americans and Japanese using genome-wide association studies (GWAS). To …

Objective: To conduct a meta-analysis of current studies that examined sex differences in
severity and mortality in patients with COVID-19, and identify potential mechanisms …

Increasing evidence indicates that the ability of cancer cells to convey biological information
to recipient cells within the tumor microenvironment (TME) is crucial for tumor progression. …